openPR Logo
Press release

Global Cancer Angiogenesis Inhibitors Market & Clinical Pipeline Insight Report

05-07-2018 07:26 AM CET | Health & Medicine

Press release from: Kuick Resarch

Global Cancer Angiogenesis Inhibitors Market & Clinical

“Global Cancer Angiogenesis Inhibitors Market & Clinical Pipeline Insight” Report Highlights:

* Angiogenesis Inhibitors: Introduction & Need in Cancer Therapy
* Modulators & Mechanism of Angiogenesis
* Classification of Angiogenesis Inhibitors
* Metronomic Therapy - A Recent Advancement in Anti-Angiogenesis Therapy
* Global Cancer Angiogenesis Inhibitors Clinical Pipeline by Company, Indication & Phase
* Global Cancer Angiogenesis Inhibitors Clinical Pipeline: 146 Drugs
* Marketed Cancer Angiogenesis Inhibitors Drugs: 11 Drugs

Download Report Sample Weblink:

https://www.kuickresearch.com/report-Global-Cancer-Angiogenesis-Inhibitors-Market-&-Clinical-Pipeline-Insight.php

For Report Sample Contact: neeraj@kuickresearch.com

Table of Contents

1. Angiogenesis: History and Quest for Treatment



2. Angiogenesis Inhibitors: An Ounce of Cure & Prevention

2.1 Hallmarks of Cancer

2.1.1 Self Sufficiency in Growth Signals

2.1.2 Insensitivity to Antigrowth Signals

2.1.3 Acquired Capability: Evading Apoptosis

2.1.4 Limitless Replicative Potential

2.1.5 Sustained Angiogenesis

2.1.6 Tissue Invasion & Metastasis

2.2 Angiogenic- Metastatic Pathway as a Target for Anti-Cancer Therapies



3. What is Angiogenesis?

3.1 Stages of Angiogenesis

3.2 Types of Angiogenesis

3.2.1 Sprouting Angiogenesis

3.2.2 Intussusceptive Angiogenesis or Splitting Angiogenesis



4. Modulators of Angiogenesis

4.1 VEGF & Angiogenesis

4.2 Platelet Derived Growth Factor

4.3 Fibroblast Growth Factors (FGFs) & FGF Receptors

4.4 Endothelins & Endothelin Receptors

4.5 Erythropoietin & Erythropoietin Receptor

4.6 Angiopoietins & Tie2 Receptor



5. Mechanism of Angiogenesis

5.1 Dilation of Existing Vessels, Increase in Vascular Permeability & Degradation of Existing Vessels

5.2 Endothelial Cells Proliferation & Migration

5.3 Assembling of Endothelial Cells, Formation of Cords & Lumen

5.4 Long-Term Survival of Vascular Endothelium

5.5 Differentiation of Vascular Endothelium to Meet Local Needs



6. Classification of Angiogenesis Inhibitors

6.1 Direct Endogenous Inhibitors of Angiogenesis

6.2 Indirect Inhibitors of Angiogenesis

6.3 Conventional Chemotherapeutic Agents

6.4 VEGF Targeted Therapy

6.5 FGF Targeted Therapies

6.6 Oncogene Targeted Therapy

6.7 Matrix Degrading & Remodeling Targeted Therapy

6.8 Stromal Tumor Associated Cell Targeted Therapy

6.9 Cell Adhesion Molecules (CAMs) Targeted Therapy

6.10 Inflammatory Angiogenesis Targeted Therapy



7. Metronomic Therapy - A Recent Advancement in Anti-Angiogenesis Therapy



8. Applications of Angiogenesis Inhibitors

8.1 Quantitation & Prognosis of Malignant Disorders

8.2 Antiangiogenic Therapies

8.2.1 Cancer

8.2.2 Interferon Alpha-2α to Treat Hemangiomas

8.2.3 Ocular Neovascularization



9. Global Angiogenesis Inhibitors Market overview

9.1 Current Market Scenario

9.2 Global Cancer Angiogenesis Inhibitors Clinical Pipeline Overview



10. Global Cancer Angiogenesis Inhibitors Market Dynamics

10.1 Favorable Market Parameters

10.1.1 Large Global Patient Pool

10.1.2 Severity of the Disease

10.1.3 Side Effects of the Existing Drugs

10.1.4 Unmet Requirement of Completely Curative Agents

10.2 Major Challenges of Cancer Angiogenesis Inhibitors Market

10.2.1 Difficulties Associated with Evaluation of Anti Angiogenic Effect of Drugs

10.2.2 Prospects of Delayed Toxicity with Long-Term Anti-Angiogenic Therapy

10.2.3 Need of the Better Therapy Models

10.2.4 Approval from Regulatory Guidelines: A Major Challenge

10.2.5 Journey of Drug from Bench to Bedside: A Matter of Money & Time



11. Concluding Remarks & Future Market Prospects



12. Global Cancer Angiogenesis Inhibitors Clinical Pipeline by Company, Indication & Phase

12.1 Unknown

12.2 Research

12.3 Preclinical

12.4 Clinical

12.5 Phase-I

12.6 Phase-I/II

12.7 Phase-II

12.8 Phase-II/III

12.9 Phase-III

12.10 Preregistration



13. Marketed Cancer Angiogenesis Inhibitors Clinical Insight by Company & Indication

13.1 Apatinib

13.2 Lenalidomide (Ladevina & Revlimid)

13.3 Pomalidomide (Imnovid & Pomalyst)

13.4 Sorafenib (Nexavar)

13.5 Thalidomide (Thaled, Thalidomide Celgene & Thalomid)

13.6 Pazopanib (Votrient)

13.7 Bevacizumab (Avastin)

13.8 Bevacizumab Biosimilar (Cizumab)

13.9 Cetuximab (Erbitux)

13.10 Axitinib (Inlyta)

13.11 Recombinant Human Endostatin (Endostar & Endu)



14. Discontinued & Suspended Cancer Angiogenesis Inhibitors Clinical Pipeline by Company & Phase

14.1 No Development Reported

14.2 Discontinued

14.3 Suspended



15. Competitve Landscape

15.1 Advenchen Laboratories

15.2 Allergan

15.3 Alnylam Pharmaceuticals

15.4 Amgen

15.5 Angstrom Pharmaceuticals

15.6 Acceleron Pharma

15.7 Biocon

15.8 Bionomics

15.9 CASI Pharmaceuticals

15.10 Celgene Corporation

15.11 Enzon Pharmaceuticals

15.12 Five Prime Therapeutics

15.13 Fujifilm Kyowa Kirin Biologics

15.14 Genentech

15.15 Genexine

15.16 Hetero Drugs

15.17 ImClone Systems

15.18 Intas Pharmaceuticals

15.19 Kyowa Hakko Kirin

15.20 Levolta Pharmaceuticals

15.21 Mabtech

15.22 Marsala Biotech

15.23 Neumedicines

15.24 Novartis

15.25 Oncobiologics

15.26 Onyx Pharmaceuticals

15.27 Pfizer

15.28 Philogen

15.29 TBG Diagnostics

15.30 Reliance Life Sciences

15.31 Roche

15.32 Samsung Bioepis

15.33 Simcere Pharmaceutical

15.34 SynCore Biotechnology

15.35 TaiRx

15.36 Taiwan Liposome

15.37 Tiltan Pharma

15.38 XBiotech

Figure 3-1: Different Stages of Involved in Angiogenesis

Figure 3-2: Different Types of Angiogenesis

Figure 3-3: Steps Involved in Sprouting Angiogenesis

Figure 3-4: Steps Involved in Splitting Angiogenesis

Figure 4-1: Different Types of Modulators of Angiogenesis

Figure 4-2: Pathway Followed by VEGF during Angiogenesis

Figure 4-3: Modulatory Pathway of FGF in Angiogenesis

Figure 4-4: Basic Pathway Followed by Modulators to Facilitate Angiogenesis

Figure 5-1: Mechanism of Angiogenesis Stimulated by Tumor Cells

Figure 6-1: Various Categories of Angiogenesis Inhibitors

Figure 8-1: Important Applications of Angiogenic Inhibitors

Figure 9-1: Global Cancer Angiogenesis Inhibitors Clinical Pipeline by Phase (%), 2016

Figure 9-2: Global Cancer Angiogenesis Inhibitors Clinical Pipeline by Phase (Numbers), 2016

Figure 9-3: Global Cancer Angiogenesis Inhibitors Suspended & Discontinued in Clinical Pipeline (%), 2016

Figure 9-4: Global Cancer Angiogenesis Inhibitors Suspended & Discontinued in Clinical Pipeline (Numbers), 2016

Figure 10-1: Favorable Parameters for Cancer Angiogenesis Inhibitors Market

Figure 10-2: Major Challenges of Cancer Angiogenesis Inhibitors Market

Figure 15-1: Advenchen Laboratories - Clinical Pipeline

Figure 15-2: Alexion Pharmaceuticals - Clinical Pipeline

Figure 15-3: Alnylam Pharmaceuticals – Clinical Pipeline

Figure 15-4: Amgen - Clinical Pipeline

Figure 15-5: Acceleron Pharma – Clinical Pipeline

Figure 15-6: Biocon - Clinical Pipeline

Figure 15-7: Bionomics – Clinical Pipeline

Figure 15-8: Casi Pharmaceutical - Clinical Development

Figure 15-9: Celgene - Clinical Pipeline

Figure 15-10: Five Prime Therapeutics – Clinical Pipeline

Figure 15-11: Fujifilm Kyowa Kirin Biologics - Clinical Pipeline

Figure 15-12: Genexine - Clinical Pipeline

Figure 15-13: Levolta Pharmaceuticals – Clinical Pipeline

Figure 15-14: Neumedicines - Clinical Pipeline

Figure 15-15: Novartis - Clinical Pipeline

Figure 15-16: Oncobiologics - Clinical Pipeline

Figure 15-17: Philogen – Clinical Pipeline

Figure 15-18: Samsung Bioepis - Clinical Pipeline

Figure 15-19: Simcere Pharmaceutical Group – Clinical Pipeline

Figure 15-20: SynCore Biotechnology – Clinical Pipeline



Table 1-1: List of the Major Events in History of Angiogenesis Inhibitors Development

Table 2-1: List of FDA Approved Drugs & Their Target Cancer

Table 4-1: List of Some Angiogenesis Inhibitors & Their Target Receptors

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
L29 - L34, First Floor
Block L,Connaught Place
New Delhi-110001
+91-11-47067990

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Cancer Angiogenesis Inhibitors Market & Clinical Pipeline Insight Report here

News-ID: 1040783 • Views: 253

More Releases from Kuick Resarch

Global Cell Therapy Market To Surpass US$ 35 Billion By 2026
Global cell therapy market is expected to surpass US$ 35 Billion by 2026 as per recent report “Global Cell Therapy Market, Clinical Trials, Therapy Price & Opportunity Insight 2026” published by Kuick Research. Increasing investment, gaining research and development activities along with new technological advancement will drive the global cell therapy market. Download Report: https://www.kuickresearch.com/report-global-cell-therapy-market,-clinical-trials,-therapy-price-and-opportunity-insight-2026.php “Global Cell Therapy Market, Clinical Trials, Therapy Price & Opportunity Insight 2026” Report Highlights: • Global Cell Therapy
Cell Therapy Market Size Growth Cell Therapy Clinical Trials Market Forecast 202 …
Cell therapies are still in the infancy stages of the clinical development and are expected to evolve in the market with a vast number of opportunities in the healthcare industry. In order to form a stable base for process evaluation and development it will be essential to understand the quality of cell based products. With an increasing number of cell therapies and clinical indications being assessed, it is clear that
Global Cell Therapy Market Size Analysis Clinical Trials Growth Forecast 2026
"Global Cell Therapy Market, Clinical Trials, Therapy Price & Opportunity Insight 2026" Report Highlights: • Global Cell Therapy Market Opportunity: More Than US$ 35 Billion by 2026 • Cell Therapy Clinical Trial Insight by Indication, Company & Country • Global Cell Therapy Clinical Pipeline: 767 Cell Therapies • Globally Marketed Cell Therapies: 25 Cell Therapies • Maximum Number of Marketed Cell Therapies In USA: 15 Therapies • Price & Product Insight By Region/Country • Regional Analysis of the Cell Therapy Market Download
CAR T Cell Therapy Changing The Cancer Oncology Drug Market Landscape
" Global CAR T Cell Therapy Market & Clinical Trials Insight 2024" Report Highlights: • CAR T-Cell Therapies Delivery Pipeline & Mechanism of Action • Sales Analysis of CAR - T Cell Therapy • CAR - T Cell Therapy Market Opportunity: US$ 700 Million • CAR-T Cell Therapies Clinical Pipeline by Company, Indication & Phase: 236 Therapies • CAR-T Cell Therapies in Highest Phase: Preclinical • Marketed CAR-T Cell Therapies: 2 ( Yescarta & Kymriah) • Global Market Scenario of

All 5 Releases


More Releases for Angiogenesis

Global Cancer Angiogenesis Inhibitors Market Size, Growth and Forecast Analytics
The study begins with a detailed overview of the market for Global cancer angiogenesis inhibitors market professional survey report 2017, including the definition, classification, and industry chain structure of “Global cancer angiogenesis inhibitors market” professional survey report 2017, and move forward to cover every aspect of this market, counting several criteria based on which the market is classified. Focusing specifically on the key trends, it further evaluates the overall performance
Download Global Cancer Angiogenesis Inhibitors Market & Clinical Pipeline Insigh …
Cancer is ever fastest growing global epidemic and one of the leading causes of death in the developed countries. It was observed that year 2015 alone witnessed more than 10 million new cancer cases. The number of new cancer cases is predicted to rise to 22 million within the next two decades. More than 60 percent of the world’s new cancer cases occur in Africa, Asia, and Central and South
Global Cancer Angiogenesis Inhibitors Market & Ongoing Clinical Pipeline Insight
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Angiogenesis: History and Quest for Treatment 2. Angiogenesis Inhibitors: An Ounce of Cure & Prevention 2.1 Hallmarks of Cancer 2.1.1 Self Sufficiency in Growth Signals 2.1.2 Insensitivity to Antigrowth Signals 2.1.3 Acquired Capability: Evading Apoptosis 2.1.4 Limitless Replicative Potential 2.1.5 Sustained Angiogenesis
Global Cancer Angiogenesis Inhibitors Market & Ongoing Clinical Pipeline Insight
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Angiogenesis: History and Quest for Treatment 2. Angiogenesis Inhibitors: An Ounce of Cure & Prevention 2.1 Hallmarks of Cancer 2.1.1 Self Sufficiency in Growth Signals 2.1.2 Insensitivity to Antigrowth Signals 2.1.3 Acquired Capability: Evading Apoptosis 2.1.4 Limitless Replicative Potential 2.1.5 Sustained Angiogenesis
Cancer Angiogenesis Inhibitors Market Cancer Angiogenesis Clinical Pipeline Repo …
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Angiogenesis: History and Quest for Treatment 2. Angiogenesis Inhibitors: An Ounce of Cure & Prevention 2.1 Hallmarks of Cancer 2.1.1 Self Sufficiency in Growth Signals 2.1.2 Insensitivity to Antigrowth Signals 2.1.3 Acquired Capability: Evading Apoptosis 2.1.4 Limitless Replicative Potential 2.1.5 Sustained Angiogenesis
Cancer Angiogenesis Inhibitors Market Sales Revenue Clinical Trials Pipeline Rep …
Cancer is ever fastest growing global epidemic and one of the leading causes of death in the developed countries. It was observed that year 2015 alone witnessed more than 10 million new cancer cases. The number of new cancer cases is predicted to rise to 22 million within the next two decades. More than 60 percent of the world’s new cancer cases occur in Africa, Asia, and Central and South